Switch to Tenofovir-based Therapy or to Continue Adefovir-based Therapy in CHB Patients with Suboptimal Response to Adefovir-based Combination?

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2017 Jan 14

PMID 28081595

Citations 1

Authors

Byung-Cheol Song

Affiliations

Soon will be listed here.

Citing Articles

A Desmethylphosphinothricin Dipeptide Derivative Effectively Inhibits and Growth.

Khomutov M, Giovannercole F, Onillon L, Demiankova M, Vasilieva B, Salikhov A Biomolecules. 2023; 13(10).

PMID: 37892133 PMC: 10604730. DOI: 10.3390/biom13101451.

References

Chang T, Liaw Y, Wu S, Schiff E, Han K, Lai C . Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52(3):886-93. DOI: 10.1002/hep.23785. View

Dienstag J, Cianciara J, Karayalcin S, Kowdley K, Willems B, Plisek S . Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003; 37(4):748-55. DOI: 10.1053/jhep.2003.50117. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2007; 45(2):507-39. DOI: 10.1002/hep.21513. View

Cho Y, Cui X, Jeong S, Song B . Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Antiviral Res. 2014; 112:8-17. DOI: 10.1016/j.antiviral.2014.09.013. View

Park J, Park S . Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol. 2015; 21(3):242-8. PMC: 4612285. DOI: 10.3350/cmh.2015.21.3.242. View

Schiff E, Lee S, Chao Y, Yoon S, Bessone F, Wu S . Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2010; 9(3):274-6. DOI: 10.1016/j.cgh.2010.11.040. View

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012; 381(9865):468-75. DOI: 10.1016/S0140-6736(12)61425-1. View

Ryu H, Lee J, Ahn S, Kim D, Lee M, Han K . Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010; 82(11):1835-42. DOI: 10.1002/jmv.21898. View

Lim Y, Yoo B, Byun K, Kwon S, Kim Y, An J . Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2015; 65(6):1042-51. DOI: 10.1136/gutjnl-2014-308435. View

10.

Wong G, Chan H, Mak C, Lee S, Ip Z, Lam A . Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013; 58(5):1537-47. DOI: 10.1002/hep.26301. View

11.

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H . Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2012; 58(1):98-107. DOI: 10.1002/hep.26180. View

12.

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann H . Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2016; 66(1):11-18. DOI: 10.1016/j.jhep.2016.08.008. View

13.

Liaw Y, Sung J, Chow W, Farrell G, Lee C, Yuen H . Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15):1521-31. DOI: 10.1056/NEJMoa033364. View

14.

. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016; 22(1):18-75. PMC: 4825166. DOI: 10.3350/cmh.2016.22.1.18. View

15.

Lai C, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C . Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003; 36(6):687-96. DOI: 10.1086/368083. View

16.

Lim Y, Byun K, Yoo B, Kwon S, Kim Y, An J . Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2015; 65(5):852-60. DOI: 10.1136/gutjnl-2014-308353. View

17.

Lee J, Park J, Kim D, Nguyen T, Hong S, Kim S . Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther. 2010; 15(2):235-41. DOI: 10.3851/IMP1510. View

18.

van Bommel F, de Man R, Wedemeyer H, Deterding K, Petersen J, Buggisch P . Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2009; 51(1):73-80. DOI: 10.1002/hep.23246. View

19.

Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S . Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010; 139(4):1207-17. DOI: 10.1053/j.gastro.2010.06.053. View

20.

Hou J, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J . Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat. 2014; 22(2):85-93. DOI: 10.1111/jvh.12313. View